4.7 Review

Axl inhibitors as novel cancer therapeutic agents

Journal

LIFE SCIENCES
Volume 198, Issue -, Pages 99-111

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2018.02.033

Keywords

Axl inhibitors; Receptor tyrosine kinase; Cancer; Targeted therapy; Small chemicals

Funding

  1. National Natural Science Foundation of China [81502276]
  2. Major Projects of Science and Technology of Health and Family Planning Commission of Hunan Province [A2017013]
  3. Natural Science Foundation of Hunan Province [2016JJ4077]
  4. Natural Science Foundation of Guangxi [2015GXNSFEA139003]

Ask authors/readers for more resources

Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers. Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Therefore, the research on Axl is promising and it is worthy of further investigations. In this review, we present an update on the Axl inhibitors and provide new insights into their latent application.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available